Sherwin-Williams on Pace for Largest Percent Increase Since November 2022 — Data Talk
Sherwin-Williams Company (SHW) is currently at $338.94, up $16.59 or 5.15%
--Would be highest close since March 28, 2024, when it closed at $347.33
--On pace for largest percent increase since Nov. 10, 2022, when it rose 7.66%
--Currently up two consecutive days; up 5.31% over this period
--Best two day stretch since the two days ending June 2, 2023, when it rose 5.73%
--Up 13.57% month-to-date; on pace for best month since Nov. 2023, when it rose 17.04%
--Up 8.67% year-to-date
--Down 3.75% from its all-time closing high of $352.16 on Dec. 31, 2021
--Up 22.82% from 52 weeks ago (July 25, 2023), when it closed at $275.96
--Down 2.42% from its 52-week closing high of $347.33 on March 28, 2024
--Up 44.24% from its 52-week closing low of $234.98 on Oct. 24, 2023
--Traded as high as $342.00; highest intraday level since April 1, 2024, when it hit $346.46
--Up 6.1% at today's intraday high; largest intraday percent increase since Nov. 10, 2022, when it rose as much as 10.3%
--Sixth best performer in the S&P 500 today
All data as of 12:32:36 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
July 23, 2024 12:49 ET (16:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks